These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35419951)

  • 1. Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.
    Yao YL; Wang YX; Yang FC; Wang C; Mao M; Gai QJ; He J; Qin Y; Yao XX; Lan X; Zhu J; Lu HM; Zeng H; Yao XH; Bian XW; Wang Y
    CNS Neurosci Ther; 2022 Jul; 28(7):1033-1044. PubMed ID: 35419951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
    Yuan L; Zhang H; Liu J; Malhotra A; Dey A; Yu B; Jella KK; McSwain LF; Schniederjan MJ; MacDonald TJ
    Mol Oncol; 2022 Feb; 16(4):1009-1025. PubMed ID: 34482626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoproteomics of short-term hedgehog signaling in human medulloblastoma cells.
    Scheidt T; Alka O; Gonczarowska-Jorge H; Gruber W; Rathje F; Dell'Aica M; Rurik M; Kohlbacher O; Zahedi RP; Aberger F; Huber CG
    Cell Commun Signal; 2020 Jun; 18(1):99. PubMed ID: 32576205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
    Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
    Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma.
    Tsiami F; Lago C; Pozza N; Piccioni F; Zhao X; Lülsberg F; Root DE; Tiberi L; Kool M; Schittenhelm J; Bandopadhayay P; Segal RA; Tabatabai G; Merk DJ
    Acta Neuropathol Commun; 2024 Aug; 12(1):125. PubMed ID: 39107797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation.
    Tan IL; Wojcinski A; Rallapalli H; Lao Z; Sanghrajka RM; Stephen D; Volkova E; Korshunov A; Remke M; Taylor MD; Turnbull DH; Joyner AL
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3392-3397. PubMed ID: 29531057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
    Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
    Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
    Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
    Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
    Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
    Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of apoptotic genes and downregulation of target genes of Sonic Hedgehog signaling pathway in DAOY medulloblastoma cell line treated with arsenic trioxide.
    Ghorbanlou M; Moradi F; Shabani R; Mehdizadeh M
    J Chemother; 2024 Oct; 36(6):506-519. PubMed ID: 38130211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the ciliary GTPase Arl13b suppresses Sonic hedgehog overactivation and inhibits medulloblastoma formation.
    Bay SN; Long AB; Caspary T
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1570-1575. PubMed ID: 29378965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
    Kieran MW
    Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.
    Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup AL; Kaur P; Tong P; Li A; Xu L; Reiter JF; Raleigh DR
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33476305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth.
    Yang F; Rodriguez-Blanco J; Long J; Swiderska-Syn M; Wynn DT; Li B; Shen C; Nayak A; Ban Y; Sun X; Suter RK; McCrea HJ; Capobianco AJ; Ayad NG; Robbins DJ
    Mol Cancer Res; 2022 Nov; 20(11):1598-1610. PubMed ID: 35925047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at
    Dobson THW; Tao RH; Swaminathan J; Maegawa S; Shaik S; Bravo-Alegria J; Sharma A; Kennis B; Yang Y; Callegari K; Haltom AR; Taylor P; Kogiso M; Qi L; Khatua S; Goldman S; Lulla RR; Fangusaro J; MacDonald TJ; Li XN; Hawkins C; Rajaram V; Gopalakrishnan V
    Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma.
    Zhu L; Yang Y; Li H; Xu L; You H; Liu Y; Liu Z; Liu X; Zheng D; Bie J; Li J; Song C; Yang B; Luo J; Chang Q
    Cancer Lett; 2022 Jun; 535():215630. PubMed ID: 35304257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures.
    Cohen JR; Resnick DZ; Niewiadomski P; Dong H; Liau LM; Waschek JA
    BMC Cancer; 2010 Dec; 10():676. PubMed ID: 21143927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.